食管癌同步放化疗的临床研究

目的探讨食管癌同步化放疗与单纯放疗治疗的临床疗效。方法 56例食管癌患者随机分为两组,其中同步放化组(3DCRT+化疗)28例,采用PF化疗方案,5-Fu 500mg/m2d1~5,DDP 20mg/m2d1~5,共2个周期,分别于放疗的第1周及第4周给予。单放组(单纯3DCRT)28例,给予单纯放射治疗。结果研究组食管癌患者治疗有效率、3年生存情况均明显优于对照组患者,且P<0.05,对比结果具有统计学意义;研究组食管癌患者经治疗后不良反应发生率为25.00%,对照组患者不良反应发生率为28.57%,且P>0.05,两组对比结果无统计学意义。结论在患者治疗过程中或治疗后出现的不良反应无明显差异情况下,对食管癌患者进行同步放化疗的综合性治疗措施,能够有效提高患者治疗效果,改善患者3年生存情况,提高患者生存质量,值得临床推广应用。

Clinical Research of Esophageal Synchronous Chemoradiotherapy

Objective To evaluate the efficacy of concurrent chemoradiotherapy and radiotherapy alone in the treatment of the esophageal cancer.Methods Select esophageal cancer patients 56 cases,randomly divided into two groups and each group 28 cases.The concurrent radiochemotherapy group： 3DCRT and 5-Fu 500mg/m2 d1-5,w1,4;DDP 20mg/m2 d1-5,w1,4.Radiotherapy alone group： the other 28 cases were treated with 3DCRT.Results In the concurrent radiochemotherapy group,the three years survival rate was significantly better than the control group and P0.05,two groups of patients compared with statistical significance;the incidence of adverse reactions in the study group was 25%,the adverse reaction rate was 28.57% in the control group,and P0.05.Conclusion For patients with esophageal carcinoma,radiotherapy combinate with chemotherapy can effectively improve the results of treatment of patients,improve patient three years survival situation,finally to improve the patients＇ quality of life,worthy of clinical application.